← Oncology Approval Tracker

FDA DECISION ·

Keytruda every six weeks

pembrolizumab · Merck

Traditional approvalTraditional conversionMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Traditional approval of the alternative 400 mg every-six-weeks regimen across approved adult solid tumor indications.

LAMPGEN ANALYSIS

Why it matters

This converts the previously accelerated alternative schedule for solid tumor uses after FDA reviewed postmarketing data.

What research teams should watch

Keep dosing-schedule conversion distinct from indication conversions and document the chosen infusion interval.

PRIMARY RECORDS

Sources